

From: Chief Officer

Sent: 02 February 2026 10:55

To: ServiceDevelopmentLead <ServiceDevelopmentLead@leics-lpc.co.uk>

Subject: FW: IMPORTANT !Update to LLR Formulary – GLP-1 Agonists (Ozempic / Mounjaro)

Importance: High

FAO: ALL LLR Pharmacy Teams

I wanted to notify you that the [LLR formulary page for GLP-1 agonists](#) has been updated by LLR ICB to reflect the following recommendations for new starts in Type 2 diabetes:

- **BMI < 35:** First choice GLP-1 agonist is **subcutaneous semaglutide (Ozempic)**
- **BMI > 35:** First choice GLP-1 agonist is **subcutaneous semaglutide (Ozempic) or subcutaneous tirzepatide (Mounjaro)**

Please could you share this update with your pharmacy teams.

This change may result in an increase in Ozempic prescribing, and community pharmacies may therefore need to liaise with wholesalers to ensure sufficient quota and stock availability.

Kind Regards

Rajshri Owen MRPharmS

Chief Officer